Cargando…

Changes in hepatitis C virus antibody titer and viral RNA load in non-Hodgkin's lymphoma patients after rituximab chemotherapy

Detalles Bibliográficos
Autores principales:	Tsutsumi, Y, Ichiki, K, Shiratori, S, Kawamura, T, Tanaka, J, Asaka, M, Imamura, M, Masauzi, N
Formato:	Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2009
Materias:	Letters to the Editors
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2728889/ https://www.ncbi.nlm.nih.gov/pubmed/18294236 http://dx.doi.org/10.1111/j.1751-553X.2008.01034.x

Ejemplares similares

Rituximab Administration and Reactivation of HBV
por: Tsutsumi, Yutaka, et al.
Publicado: (2010)

Rituximab in the treatment of non-Hodgkin’s lymphoma
por: Hauptrock, Beate, et al.
Publicado: (2008)

Rituximab induced hypoglycemia in non-Hodgkin's lymphoma
por: Hussain, Badrudeen M, et al.
Publicado: (2006)

Expanded use of rituximab in the management of non-Hodgkin lymphoma
por: Eichenauer, Dennis A, et al.
Publicado: (2009)

Characteristics of pulmonary complications in non-Hodgkin’s lymphoma patients treated with rituximab-containing chemotherapy and impact on survival
por: Keefer, Kimberly, et al.
Publicado: (2018)

Pneumocystis jirovecii pneumonia in non-Hodgkin’s lymphoma after rituximab-based chemotherapy: a case series
por: Zhang, Qianying, et al.
Publicado: (2022)

B cell non-Hodgkin's lymphoma: rituximab safety experience
por: Mohrbacher, Ann
Publicado: (2005)

Positive correlation between Merkel cell polyomavirus viral load and capsid-specific antibody titer
por: Pastrana, Diana V., et al.
Publicado: (2011)

Use of Rituximab in Autoimmune Hemolytic Anemia Associated with Non-Hodgkin Lymphomas
por: Fozza, Claudio, et al.
Publicado: (2011)

5-Azacytidine partially restores CD20 expression in follicular lymphoma that lost CD20 expression after rituximab treatment: a case report
por: Tsutsumi, Yutaka, et al.
Publicado: (2016)

The Effect of Rituximab on Antiphospholipid Titers in Patients with Antiphospholipid Syndrome
por: Youkhana, Kimberley, et al.
Publicado: (2023)

How the discovery of rituximab impacted the treatment of B-cell non-Hodgkin’s lymphomas
por: Mohammed, Raihan, et al.
Publicado: (2019)

Rituximab maintenance in relapsed or refractory follicular non-Hodgkin’s lymphoma: the evidence of its therapeutic value
por: Ardeshna, Kirit M.
Publicado: (2007)

ABO-incompatible liver transplantation using only rituximab for patients with low anti-ABO antibody titer
por: Lee, Boram, et al.
Publicado: (2019)

Cold Autoimmune Hemolytic Anemia due to High-grade non Hodgkin's B cell Lymphoma with Weak Response to Rituximab and Chemotherapy Regimens
por: Nazel Khosroshahi, Behzad, et al.
Publicado: (2015)

Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in human immunodeficiency virus-associated, B-cell non-Hodgkin lymphoma
por: Sparano, Joseph A., et al.
Publicado: (2020)

Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi
por: Gotti, Manuel, et al.
Publicado: (2023)

Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness
por: Badin, Firas, et al.
Publicado: (2010)

Pneumocystis jirovecii pneumonia in HIV-uninfected, rituximab treated non-Hodgkin lymphoma patients
por: Wei, Kai-Che, et al.
Publicado: (2018)

Denileukin Diftitox in Combination with Rituximab for Previously Untreated Follicular B-cell Non-Hodgkin’s Lymphoma
por: Ansell, Stephen M., et al.
Publicado: (2011)

Assessment of antibody titers and immunity to Hepatitis B in children receiving chemotherapy
por: Shams Shahemabadi, A, et al.
Publicado: (2012)

Sarcoid Reactions after Chemotherapy for Hodgkin’s Lymphoma
por: Wirk, Baldeep
Publicado: (2010)

The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models
por: Hicks, Stuart W., et al.
Publicado: (2017)

(177)Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma
por: Malenge, Marion M., et al.
Publicado: (2020)

Male fertility after VAPEC-B chemotherapy for Hodgkin's disease and non-Hodgkin's lymphoma.
por: Radford, J. A., et al.
Publicado: (1994)

An evaluation of the potential for drug–drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma
por: Darwish, Mona, et al.
Publicado: (2014)

RELATIONSHIP BETWEEN SARS-COV-2 VIRAL LOAD, ANTIGEN POSITIVITY AND INFECTIOUS TITER
por: Germuskova, Z., et al.
Publicado: (2023)

Viral antibody titers, immunogenetic markers, and their interrelations in multiple sclerosis patients and controls
por: Alpérovitch, A., et al.
Publicado: (1991)

Combined chemotherapy in 76 children with non-Hodgkin's lymphoma excluding Burkitt's lymphoma.
por: Büyükpamukçu, M., et al.
Publicado: (1987)

Copanlisib plus rituximab combination therapy vs. rituximab monotherapy for relapsed indolent non-Hodgkin lymphoma: a cost-effectiveness analysis
por: Tang, Xiao, et al.
Publicado: (2022)

Standard Operating Procedure for In-house Preparation of (131)I-rituximab for Radioimmunotherapy of Non-Hodgkin's Lymphoma
por: Pickford, Matthew D., et al.
Publicado: (2012)

Development of DOTA-Rituximab to be Labeled with (90)Y for Radioimmunotherapy of B-cell Non-Hodgkin Lymphoma
por: Johari doha, Fariba, et al.
Publicado: (2017)

The Impact of Chemotherapy on Hepatitis B Antibody Titer in Patients with Hematological Malignancies
por: Yağcı, Münci, et al.
Publicado: (2015)

The cost-effectiveness of high dose chemotherapy in the treatment of relapsed Hodgkin's disease and non-Hodgkin's lymphoma
por: Beard, S M, et al.
Publicado: (2000)

Extracorporeal Membrane Oxygenation with rituximab‐combined chemotherapy in AIDS‐associated primary cardiac lymphoma: A case report
por: Fuseya, Hoyuri, et al.
Publicado: (2021)

Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma
por: Vakkalanka, Bhanu, et al.
Publicado: (2011)

Occurrence of sarcoidosis after chemotherapy for non-Hodgkin lymphoma
por: Cho, Hyungwoo, et al.
Publicado: (2016)

Management of Non-Hodgkin's Lymphoma in Maxillofacial Region with Chemotherapy
por: Moin, Ayesha, et al.
Publicado: (2017)

Combination chemotherapy for intermediate and high grade non-Hodgkin's lymphoma.
por: Dhaliwal, H. S., et al.
Publicado: (1993)

Consolidative proton therapy after chemotherapy for patients with Hodgkin lymphoma
por: Hoppe, B. S., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bs59vch6pjaolps44li39t0os1